Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels of the suppressor of apoptosis Bcl-2 and relatively high levels of the apoptosis inducer Bax (Chresta et al., 1996) . To determine whether the absence of Bcl-2 in these cell lines makes them highly susceptible to drug-induced apoptosis, Bcl-2 was expressed ectopically in the 833K testicular germ cell tumour cell line. Stable overexpressing clones were isolated and three clones were studied further. Surprisingly, Bcl-2 overexpressing cells were sensitized to chemotherapy-induced apoptosis compared to the parental and vector control cells. Analysis of potential mechanisms of sensitization revealed there was a reciprocal downregulation of the endogenously expressed Bcl-X L in the Bcl-2 overexpressing clones. Downregulation of Bcl-X L to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold. Our results indicate that Bcl-2 and Bcl-X L have dierent abilities to protect against chemotherapyinduced apoptosis in testicular germ cell tumours. In contrast to ®ndings in some tumour cell types, Bcl-2 did not act as a gatekeeper to prevent entry of p53 to the nucleus.
Introduction
Disseminated testicular cancer, in contrast to the majority of solid tumours, is highly sensitive to combination chemotherapy and is cured in greater than 80% of cases (Einhorn, 1990) . Recently it has been suggested that many chemotherapeutic agents exert their cytotoxicity through activtion of apoptosis (Dive and Hickman, 1991) . Signi®cantly, chemosensitive testicular germ cell tumours (TGCT) are hypersentitive to drug-induced apoptosis Chrestra et al., 1996) .
The precise mechanisms that control apoptosis have not been elucidated. However, studies in several eukaryotic systems have demonstrated that apoptosis is regulated by genetic programs involving both activators and suppressors of cell death. Bcl-2 was the ®rst member of a rapidly expanding family of proteins which have been demonstrated to regulate apoptosis in response to chemotherapy both in vivo and in vitro (Fisher et al, 1993 ; reviwed in Kroemer, 1997; Reed, 1997) . Enforced overexpression of Bcl-2, or its homologue Bcl-X L , have been demonstrated to delay apoptosis and in some cases to provide a true survival advantage after many diverse stimuli, including chemotherapeutic agents, g-irradiation and growth factor deprivation (Lock and Stribinskiene, 1996; Simonian et al., 1997b; Walker et al., 1997; Yin and Schimke, 1995) . Conversely, overexpression of the apoptosis promoting members of the Bcl-2 family, Bax and Bak, have been demonstrated to counteract the protective eect of Bcl-2 and Bcl-X L (reviewed in Farrow and Brown, 1996; Korsmeyer, 1995) . Genetic manipulation has shown that the relative ratio of these dimers can determine the susceptibility of the cell to apoptosis in response to a wide variety of stimuli (Farrow and Brown, 1996; Korsmeyer, 1995; Oltvai and Korsmeyer, 1994) . From early studies employing immunoprecipitation and yeast two-hybrid analysis it was noted that the Bcl-2 family of proteins form homodimers and heterodimers and it was suggested this was important for function (Oltvai et al., 1993; Yang et al., 1995) . However, more recently Bcl-2 family members have been demonstrated to interact with non-Bcl-2 family members (e.g. raf-1, APAF1) and to regulate apoptosis independently of heterodimerization with each other (Knudson and Korsmeyer, 1997; Simonian et al., 1996 Simonian et al., , 1997a Wang et al., 1996; Zou et al., 1997) . In addition, following an apoptotic stimuli Bax and Bcl-X L are redistributed to intracellular membranes an event which is important for function Wolter et al., 1997) .
Genetic alterations that prevent or delay apoptosis can render tumour cells relatively resistant to the cytotoxic eects of chemotherapy agents. High levels of Bcl-2 and lack of Bax expression have been reported in a wide variety of human cancers and may be associated with poor response to chemotherapy in the clinic (reviewed in Reed, 1994) . We have previously shown that testicular tumours have high levels of Bax and low to undetectable levels of Bcl-2 compared to drug resistant tumours of the human bladder (Chresta et al., 1996) . This may be related to the origin of these tumours, from immature cells of the testis, which similarly do not express Bcl-2 (Hockenbery et al., 1991; Lu et al., 1993) . To determine whether the absence of Bcl-2 is a major determinant of chemosensitivity in these tumours we have investigated the eect of ectopically overexpressing Bcl-2 in a human TGCT cel line 833K. Surprisingly, when the response of the Bcl-2 overexpressors to chemotherapy was investigated it was found that Bcl-2 sensitized the cells to chemotherapy-induced apoptosis and increased cell death measured by a colony forming assay.
Results
The endogenous level of Bcl-2 in TGCT's (GH, GCT27, 833K, NT2 and 2102EP) is signi®cantly lower than in apoptosis resistant RT4 bladder tumour cells (Figure 1) . To test the hypothesis that absence of Bcl-2 expression is responsible for the apoptosis susceptible phenotype of TGCT, we ectopically overexpressed Bcl-2 in TGCT (833K) cells. Ten G418 resistance colonies were analysed for Bcl-2 expression. Of these, three clones expressed Bcl-2 at levels equivalent to those found in apoptosis-resistant RT4 (Figure 1 ). Three clones overexpressing Bcl-2 and three vector control clones were selected for further study. The cell cycle distribution, cell doubling time and cloning eciency of the Bcl-2 overexpresing cells were similar to that of the vector control clones (Table 1) . Thus overexpression of Bcl-2 in TGCT does not prevent entry into S-phase or colony formation as has been found in some tumour types (O'Reilly et al., 1996; Pietenpol et al., 1994) .
Overexpression of Bcl-2 enhances etoposide-induced apoptosis
In contrast to ®ndings in many tumour cell systems (Fisher et al., 1993; Hashimoto et al., 1995; Kamesaki et al., 1993; Simonian et al., 1997b) , overexpression of Bcl-2 in TGCT resulted in an increase in etoposideinduced apoptosis measured by both analysis of morphology and release of low molecular weight DNA fragments (indicative of endonuclease activation ± see Materials and methods). The percentage of apoptosis was increased approximately fourfold from 11% in the parental and vector control cells to 38% in the Bcl-2 overexpressing clones 4 h after drug treatment (Figure 2a) . The level of topoisomerase II associated single strand breaks produced by a 1 h treatment with 4 mM etoposide was approximately equal in the parental and transfected cells (results not shown). This suggests that Bcl-2 is enhancing apoptosis at a step in the cell death pathway subsequent to etoposide-induced DNA damage. Bcl-2 overexpression also promoted apoptosis induced by the non-genotoxic agent N-methylformamide and the vinca alkaloid, vincristine. Apoptosis induced by a 20 h treatment with 300 mM NMF was increased by 1.7-fold by Bcl-2 overexpression, whilst that induced by a 20 h treatment with 10 mg/ml Vincristine was increased by 1.4-fold.
Bcl-2 has previously been demonstrated to delay but not inhibit chemotherapy-induced death under certain circumstances (Lock and Stribinskiene, 1996; Yin and Schimke, 1995) . In order to determine if the enhancement of etoposide induced apoptosis was just an alteration in the kinetics of cell death we used a long-term survival assay, measuring the clonogenic potential of the cells. As can be seen in Figure 2b , following etoposide treatment, all Bcl-2 overexpressing clones showed a 2 ± 3-fold greater loss of clonogenicity compared to vector controls (and parental cells). Enhancement of cytotoxicity was not limited to the topoisomerase poison etoposide. Bcl-2 overexpression also enhanced sensitivity to cis-platin by 2.2-fold ( Figure 2c ).
Analysis of subcellular localization of Bcl-2 and p53 in Bcl-2 overexpressing TGCT The Bcl-2 clone used in these studies has been sequenced and found to be wild type. It has also been shown to be functional in other cell types. It suppresses apoptosis in a Xenopus oocyte cell free assay and inhibits dexamethasone-induced apoptosis in the human lymphoblastoid cell line CEM-C7A (Cosulich et al., 1996 and Dr P Hedge personal communication) . Although the actual mechanism by which Bcl-2 functions is as yet not fully understood, the location of this protein in the mitochondria appears to be important for function (Kluck et al., 1997; Yang et al., 1997; Zhu et al., 1996) . To determine if the ectopically expressed Bcl-2 was localized in the mitochondria we used immunostaining for Bcl-2 and co-stained with a dye which localizes to active mitochondria (mito-tracker). The staining pattern in the TGCT overexpressing Bcl-2 transfects was compared to that of RT4, a bladder tumour cell line which constitutively expresses Bcl-2. Figure 3d ,g show that Bcl-2 co-localizes with the mitochondrial marker in both the Bcl-2 overexpressing TGCT cells and in the RT4 bladder carcinoma. RT4 was used as a positive control because we have demonstrated, using antisense, that Bcl-2 protects against drug-induced apoptosis in this cell type (Arriola, manuscript in preparation). Recently, Bcl-2 has been shown to inhibit translocation of p53 to the nucleus and this has been suggested to be important for function (Beham et al., 1997) . However, we did not ®nd this to be the case in either RT4, where Bcl-2 inhibits apoptosis ( Figure 3i ) or in 833K.Bcl-2 clones, where Bcl-2 promotes apoptosis ( Figure 3f ).
Eect of Bcl-2 overexpression on other Bcl-2 family members
Several reports have suggested reciprocity in the expression of Bcl-2 and Bcl-X L Chao et al., 1995; Han et al., 1996) . We therefore determined if there was any evidence for alteration in the expression of Bcl-X L in the Bcl-2 overexpressing clones. In addition, as Bcl-2 has been reported to exert its eects through interaction with pro-apoptotic members of the Bcl-2 family Bak and Bax, we analysed if the expression of these partners had changed. As can be seen in Figure 4 , Bax protein was uniformly expressed in all lines and similar results were found for Bak (data not shown). However, in the Bcl-2 overexpressing cells there was a reciprocal downregulation of the expression of Bcl-X L that was directly related to the levels of Bcl-2 overexpression ( Figure 4a ).
Downregulation of Bcl-X L causes sensitization to etoposide-induced apoptosis
To investigate the importance of Bcl-X L in 833K cells, Bcl-X L was downregulated using an antisense phosphorothioate oligodeoxynucleotide to the coding region of the Bcl-X L mRNA (Dibbert et al., 1998) . Cells were treated with the transfecting agent alone (lipofectin) or with a scrambled (SC) sequence oligonucleotide as controls. 833K cells in which Bcl-X L expression had been downregulated ( Figure 5a ) were treated with Etoposide (IC 50 ) for 4 h. Apoptosis was measured by caspase activation as described in Materials and methods. Bcl-X L downregulation resulted in a twofold increased sensitivity of 833K cells to Etoposide induced 
Discussion
We and others have previously shown that testicular tumours are exquisitely sensitive to drug-induced apoptosis Chresta et al., 1996) . TGCT cells express signi®cantly lower levels of Bcl-2 than other solid tumour types Chresta et al., 1996, and Figure 1) . In this study, we have determined if the absence of Bcl-2 in TGCT cells plays a key role in their susceptibility to drug-induced apoptosis. A TGCT (833K) cell line was engineered to overexpress Bcl-2 to similar or greater levels than found in resistant tumours of transitional carcinoma of the bladder.
Surprisingly, when the sensitivity of the Bcl-2 overexpressing transfects to etoposide or cis-platin was studied, they were found to be more sensitive than the vector controls. The long-term survival of 833K.Bcl-2 was on average 2 ± 3-fold lower than that of 833K.Neo after etoposide or cis-platin treatment and the cells were fourfold more sensitive to etoposideinduced apoptosis in short term apoptosis assays (4 h). Susceptibility of tumour cells to drug induced apoptosis has been suggested to be controlled by the relative levels and dimerizations of the Bcl-2 family members. We have investigated several parameters which could potentially aect the sensitivity of the Bcl-2 overexpressing transfects to chemotherapy.
Bcl-2 has previously been demonstrated to exert a growth inhibitory activity on tumour cells and to prevent re-entry into the cell cycle from a G 0 -like state (O'Reilly et al., 1996; Pietenpol et al., 1994) . Thus, Bcl-2 itself can result in a reduction in colony formation in clonogenic assays. However, in contrast to the earlier studies, Bcl-2 overexpression per se did not prevent colony formation in TGCT (Table 1 and Figure 2 ). Rather, it appears that the eects of Bcl-2 Figure 3 Subcellular localization of Bcl-2, Bcl-X L and p53 in 833K.neo, 833K.Bcl-2 and RT4. Cells grown as monolayers on microscope slides were ®xed in methanol acetone (1 : 1) and then examined by¯uorescence microscopy. Panels a, b, and c are 833K cells (TGCT) transfected with vector control. Panels d, e and f are 833K cells transfected with Bcl-2 and panels g, h and i are RT4 cells (TCC) which endogenously overexpress Bcl-2. Panels a, d and g have been stained with Hoechst 3258 to show the position of the nucleus (blue) and with mito-tracker red CMXRos to show the position of mitochondria (red). Bcl-2 was detected using a mouse antihuman antibody and a FITC conjugated secondary antibody (green). Each ®eld was analysed independently at the appropriate wavelength for FITC and MitoTracker and then the two images overlaid. The orange-yellow staining (depending on the level of Bcl-2) shows that Bcl-2 co-localizes with the mitochondria in both 833K.Bcl-2 and RT4. Panels b, e and h show nuclear staining using Hoechst 33258 (blue) and a punctate cytoplasmic staining for Bcl-X L in all three cell types. Bcl-X L was detected using a rabbit polyclonal antibody and a Cy TM 3-conjugated secondary antibody (red). Note the much reduced expression of Bcl-X L in the Bcl-2 overexpresing clones (panel e). Panels c, f and i show the nuclear localization of p53 in all cell types. p53 was detected using a mouse monoclonal Ab and a Cy TM 3-conjugated secondary antibody (red)
are exerted through an enhancement of apoptosis not a decrease in colony forming ability. We have shown that Bcl-2 enhances apoptosis just 4 h after drug treatment and that the degree of enhancement in etoposide-induced apoptosis by Bcl-2 overexpression (approximately fourfold ± from 11 ± 38% at 4 h after drug treatment) is in good agreement with the increment in cytotoxicity measured by clonogenic assays. This is the ®rst observation to our knowledge, of increased sensitivity to drug-induced apoptosis by Bcl-2 overexpression. Why should Bcl-2 enhance apoptosis? One trivial explanation is that the Bcl-2 clone used in our study is mutated. However, this has been ruled out because the Bcl-2 cDNA used in this work has been demonstrated to be wild-type by sequencing and functional as a suppressor of drug-induced apoptosis in other systems (e.g. CEM-C7 human lymphoblastic leukaemic cells) (Cosulich et al., 1996) and Drs P Hedge and Ged Brady personal communication). Thus the apoptosis activating eects of Bcl-2 appear to depend on the cell type where it is expressed.
Recently two studies have indicated Bcl-2 may not always function as a suppressor of apoptosis. Firstly, Chen et al. have described activation of apoptosis by Bcl-2 following cleavage by caspase-3 which converts Bcl-2 into Bax-like death eector (Cheng et al., 1997) . However, there was no evidence for proteolysis of Bcl-2 in the overexpressing 833K cells following drug treatment suggesting this is not the mechanism of enhacement of apoptosis in the TGCT cell line (data not shown). Secondly, Uhlmann et al. showed that a Bcl-2 cDNA clone lacking the extensive 3' and 5' untranslated regions (UTR's) possessed a potent cell death activity in transient transfects of several cell types (human embryonal kidney, foetal lung, breast adenocarcinoma and prostate carcinoma (Uhlmann et al., 1998) . This eect appears to be related to the very high expression of Bcl-2 that occurs in transient (but not stable) transfects when the negative regulatory UTR regions are deleted (Uhlmann et al., 1998) . Our results are similar to those of Uhlmann et al., however, we ®nd Bcl-2 to behave as an activator of drug-induced apoptosis in stable transfects. In addition in the TGCT cells the eects of Bcl-2 overexpression are only manifested when cells are also treated with a chemotherapeutic agent.
A body of recent evidence suggests that the location of Bcl-2-family members is important for function Wolter et al., 1997; Zhu et al., 1996) . Bcl-2 itself is usually associated with several membrane fractions, including the nucleus, endoplasmic reticulum and mitochondria, the latter location apparently being important for function Zhu et al., 1996) . To determine if the overexpressed Bcl-2 was targeted to mitochondria, dual staining for Bcl-2 and mitochondria was performed. As can be seen in Figure  3 , Bcl-2 and the mitochondria speci®c dye co-localize. Thus, failure to protect against drug-induced death is not a result of lack of targeting to appropriate membranes. We have also shown that the subcellular location of Bcl-2 is the same in testicular tumour cells, where it promotes apoptosis (TGCT), and bladder tumour cells where it inhibits apoptosis (TCC-RT4) (Figure 3 ). Activation rather than suppression of apoptosis could also occur if the transfected Bcl-2 in the testis tumours could not function, for example, due to lack of an essential post-translational modi®cation step (Haldar et al., 1995 (Haldar et al., , 1996 , but could still compete for molecules to which it (and presumably Bcl-X L ) usually bind to suppress the death pathway. Whilst we cannot rule out that Bcl-2 is inactive due to postranslational modi®cation, the immunostaining data suggest it is localized correctly.
A further mechanism by which Bcl-2 could regulate apoptosis in TGCT is by aecting wild-type p53 function, either by competing with p53 for binding to binding protein 2 (53BP2) or by restricting access of p53 to the nucelus (Beham et al., 1997; Naumovski and Cleary, 1996) . 53BP2 is located in the cytoplasm where it can presumably regulate entry of p53 into the nucleus. However, as can be seen in Figure 3 , p53 is predominantly in the nucleus in both TGCT cells with exogenously overexpressed Bcl-2 and RT4 cells with high endogenous levels of Bcl-2. Thus neither Bcl-2 nor 53BP2 appear to be able to restrict entry of p53 to the nucleus. This is in contrast to studies in human prostate cancer cells where overexpressed Bcl-2 acts as a`gatekeeper' to prevent entry of p53 into the nucleus (Beham et al., 1997) .
Finally, apoptosis susceptibility is regulated by the relative levels of Bcl-2 family members. We therefore determined if the balance of protein partners had been altered. The expression of the pro-apoptotic proteins Bak and Bax was unchanged. However, as can be seen in Figure 4 , the expression of Bcl-X L shows reciprocal expression to that of Bcl-2 (compare clone D2 with B6 and B5). Similar ®ndings have been reported in the thymus and spleen of Bcl-2 and Bcl-X L transgenic mice suggesting that Bcl-2 and Bcl-X L expression is coordinated in an inverse fashion (Chao et al., 1995) . Although Bcl-2 and Bcl-X L can substitute for each other in many in vitro assays it is clear that during development the expression of the two proteins are dierentially regulated (Krajewski et al., 1994 (Krajewski et al., , 1995 . This raises the important question of whether the two molecules have distinct functions. It has been shown that in certain cell types the two proteins show dierent potencies in repression of apoptosis. This was ®rst demonstrated by Gottschalk et al. who showed Bcl-X L but not Bcl-2 could repress immunosuppressant-induced apoptosis in murine B-cells (Gottschalk et al., 1994) . More recently Bcl-X L has been demonstrated to be a more ecient repressor of chemotherapy-induced apoptosis in murine lymphoid cells engineered to overexpress either Bcl-2 or Bcl-X L (Simonian et al., 1997b) . Interestingly, the dierential protection depends on the mechanism of action of the drug employed, Bcl-X L was up to 50% more ecient than Bcl-2 in protection against etoposide and cis-platin induced apoptosis but had similar ecacy against g-irradiation or vinca-alkaloid-induced apoptosis (Simonian et al., 1997b) . Here we show that the TGCT cells with downregulated Bcl-X L were approximately fourfold more sensitive to etoposide induced apoptosis and 1 ± 2-fold more sensitive to the non-genotoxic agent NMF and the vinca alkaloid Vincristine. The importance of Bcl-X L rather than Bcl-2 as a determinant of chemoresistance is also implicated by studies of drug resistant HL-60 human promyelocytic leukaemia cells and B9 human myeloma cells (Han et al., 1996; Schwarze and Hawley, 1995) . Our results, in which we achieve a twofold sensitization to apoptosis by downregulation of Bcl-X L (Figure 5 ), similarly support a key role for Bcl-X L in modulation of drug sensitivity. In testicular tumours Bcl-2 could not substitute for Bcl-X L in the suppression of drug-induced apoptosis.
In conclusion, our data suggest a scenario in which Bcl-X L is an important protector against chemotherapy-induced apoptosis in TGCT. Bcl-2 does not appear to be able to substitute for Bcl-X L , whether this is because it is not activated in these cells or necessary cofactors, e.g. APAF's are limiting is a subject of future studies. The mechanism by which Bcl-2 promotes apoptosis may in part be the reciprocal downregulation of Bcl-X L . Certainly downregulation of Bcl-X L by AS oligonucleotides can enhance drug-induced apoptosis. However, the overexpressed Bcl-2 may also compete with Bcl-X L for other proteins necessary for the suppression of apoptosis. Our results suggest the role Bcl-2 family members have in protection against apoptosis is cell type speci®c. As TGCT are one of the few curable solid tumours it also suggests caution in the interpretation of some authors that tumours with Bcl-X L rather than Bcl-2 are likely to be the more dicult to treat (Simonian et al., 1997b) . It remains to be seen whether drug resistant TGCT will be found to express higher levels of Bcl-X L . Our results suggest Bcl-X L will form a useful target to augment chemotherapy in this tumour type.
Materials and methods

Cell culture
Characteristics of cell lines used are as detailed previously (Chresta et al., 1996) . All cell lines were grown routinely as monolayers in RPMI 1640 medium with 10% (v/v) heat inactivated fetal calf serum, 2 mM glutamine, at 378C in a humidi®ed atmosphere of 5% CO 2 . Transfected clones of 833K were grown under identical conditions in the presence of 250 mg/ml G418. Cells were used over a maximum of 12 passages in order to minimize changes which might occur as a result of long term culture.
Transfection 833K cells were transfected with the pcDNA3 plasmid containing a cDNA of the open reading frame of human bcl-2 (a kind gift from S Cosulich) or vector control (833K.neo cells). Transfections were carried out by lipofection with the Tfx TM -50 reagent (Promega) as described by the manufacturer. After 2 ± 3 weeks selection, single cell clones were isolated, expanded and frozen stocks were made.
Bcl-X L antisense treatment of 833K TGCT cells
An antisense phosphorothioate oligodeoxynucleotide to the coding region of the Bcl-X L mRNA was used (Dibbert et al., 1998) kindly provided by Dr Uwe ZangemeisterWittke, Department of Oncology, University Hospital Zurich, Switzerland. Sequence of antisense Bcl-X L , 5'-TGT ATC CTT TCT GGG AAA GC-3'; and scrambled Bcl-X L , 5'-TAA GTT CCG ATG CGA CTT GT-3'. Cells were transiently transfected using 7 mg/ml lipofectin (Gibco BRL) in 1% serum containing medium (Optimem). Cells were treated with the oligonucleotides (antisense or scrambled) or vehicle control (water) (450 nM) for 70 h. They were then either treated with etoposide or vehicle control (DMSO) for 4 h and lysates prepared for caspase assays and immunoblotting, to determine Bcl-X L levels.
Immunoblotting
Cells were detached by scraping into ice cold versene and collected by centrifugation. Cells were rinsed in ice cold PBS containing the following protease inhibitors: aprotinin (1%), benzamidine (1 mM), phenylmethylsulphonyl¯uoride (1 mM), trypsin/chymotrypsin inhibitor (10 mg/ml) then resuspended in 200 ml of PBS with protease inhibitors and sonicated using a Soniprep 150 (MSE) for 10 s at 12 microns, allowed to cool, then sonicated again for 10 s at 16 microns. Protein concentration was determined using a BioRad protein assay kit and 20 mg of protein used per sample. Samples were boiled for 5 min in SDS sample buer and then electrophoresed on 1 mm mini polyacrylamide gels at 120 V for 2 h. Proteins were transferred to Immobilon-P membrane at 80 V for 1.5 h.
Antibodies
The antibodies used for this study were, Bcl-2: or FITCconjugated anti-human Bcl-2 monoclonal Ab-124 (1 : 25 for immunostaining) from Dako (High Wycombe, UK); Bax: anti-human Bax polyclonal antibody from Pharmingen (1 : 50 for immunostaining) (San Diego, USA); Bcl-X: antihuman Bcl-X polyclonal antibody from Transduction Laboratories (1 : 50 for immunostaining) (Exeter, UK); p53: anti-human p53 DO1 monoclonal antibody from Oncogene Science (Cambridge, USA) (1 : 200 for immunostaining). Goat anti-rabbit or rabbit anti-mouse horse radish peroxidase conjugated secondary antibodies from Dako (High Wycombe, UK) were used as described by the manufacturers and bands were visualized using ECL reagents from Amersham (UK). For immuno¯uorescence, Cy TM -conjugated donkey anti-mouse or goat anti-rabbit secondary antibodes were used (Jackson Immunoresearch, Pennsylvania, USA). For mitochondria staining, Mito Tracker Red CMXRos from Molecular Probes (Oregon, USA) was used.
Cytotoxicity assay
The drugs used were Etoposide (Sigma) and cis-Platin (Sigma). Drug sensitivity was measured by clonogenic assay. 1000 cells were plated in 6-well plates (2 cm 2 ) and allowed to adhere overnight. They were then treated for 1 h with the indicated drug or appropriate vehicle control. The drug was then washed from the cells with two changes of PBS and the cells reincubated in fresh medium for 10 ± 14 days. Colonies were stained with methylene blue and colonies of greater than 50 cells were counted. Results are the mean and standard deviation of three independent experiments and triplicate plates were used in each individual experiment.
DNA fragmentation ®lter binding assay (FBA)
Apoptosis was quanti®ed using the ®lter binding assay (FBA) which is an assay of endonuclease activation (Bertrand et al., 1991) . The assay measures the percentage of low molecular weight DNA by size separation through a 2 mm ®lter; at pH 10, high molecular weight DNA is retained on the ®lter. Etoposide-induced topoisomerase associated DNA damage does not result in elution of DNA through the ®lter. This type of DNA damage is not revealed until after treatment with proteases and incubation of DNA at pH 12.1 to denature the DNA. We have previously shown apoptosis quanti®ed by this assay corresponds with percentage apoptosis determined by counting trypan-blue-negative/Hoescht 33258 positive cells (Chresta et al., 1996) . Cells in early logarithmic phase growth were labelled for 24 h with 0.015 mCi [ 14 C]thymidine/ml, wahsed and reincubated in fresh medium for 1 h. Cells were then treated with 25.7 mM etoposide for 1 h, washed with PBS (378C) and reincubated in fresh medium at 378C until harvested at 4 h.
Determination of caspase activation
The substrate used was Ac-DEVD-AMC from Calbiochem/Novabiochem which was made to 5 mM stock in DMF. On the day of the assay, substrate stock was diluted in water to 500 mM and kept on ice. 20 mg of cell lysate were diluted to equal volumes (20 ml) in NP40 lysis buer (NET) and 1/10th of the volume of substrate was added. Exactly 10 min later, the reaction was stopped by adding the mix into 2 ml of water. Fluorescence was read on thē uorimeter at an excitation wavelength of 380 nm and emission wavelength of 460 nm.
Immunostaining 10 6 cells/ml were seeded onto eight chamber slides (Falcon) and incubated at 378C overnight to adhere. For experiments in which mitochondrial staining was studied the cells were incubated with a 1 : 250 dilution of MitoTracker in culture medium for 30 min at 378C. They were rinsed once with PBS and ®xed in methanol:acetone solution (1 : 1) for 10 min at room temperature. Fixed cells were rinsed twice with PBS then incubated with antibody diluted in PBS with 0.1% fetal calf serum for 1 h at room temperature before rinsing with PBS and incubating with¯uorescent conjugated secondary antibody for 1 h at room temperature. Cells were then washed with PBS and DNA stained with Hoescht 33258 (1 mg/ml in PBS) for 5 min.
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